China Resources Pharmaceutical Group (STU:640) Other Long-Term Liabilities: €403 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:640 China Resources Pharmaceutical Group Ltd STU:640
62 GF Score
Price €0.45
GF Value €0.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group Other Long-Term Liabilities?

China Resources Pharmaceutical Group STU:640 -0.87% 62 Other Long-Term Liabilities is €403 Mil as of Dec. 2025. GuruFocus rates STU:640 with a GF Score™ of 62/100 and a GF Value™ of €0.64 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China Resources Pharmaceutical Group's other long-term liabilities for the quarter that ended in Dec. 2025 was €403 Mil.

China Resources Pharmaceutical Group's quarterly other long-term liabilities increased from Dec. 2024 (€399 Mil) to Jun. 2025 (€408 Mil) but then declined from Jun. 2025 (€408 Mil) to Dec. 2025 (€403 Mil).

China Resources Pharmaceutical Group's annual other long-term liabilities increased from Dec. 2023 (€362 Mil) to Dec. 2024 (€399 Mil) and increased from Dec. 2024 (€399 Mil) to Dec. 2025 (€403 Mil).

China Resources Pharmaceutical Group Other Long-Term Liabilities Related Terms

China Resources Pharmaceutical Group Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for China Resources Pharmaceutical Group's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group Other Long-Term Liabilities Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 346.94 347.43 362.19 399.48 403.14

China Resources Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362.19 356.08 399.48 408.18 403.14
STU:640
62GF Score
China Resources Pharmaceutical Group Ltd STU:640
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Pharmaceutical Group Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €403 Mil mean?
China Resources Pharmaceutical Group (STU:640) has a Other Long-Term Liabilities of €403 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's Other Long-Term Liabilities too high?
China Resources Pharmaceutical Group's current Other Long-Term Liabilities is €403 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Other Long-Term Liabilities compare to ZTS?
China Resources Pharmaceutical Group's Other Long-Term Liabilities of €403 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current Other Long-Term Liabilities is €403 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.45 — trading 29.1% below its estimated fair value. The current Other Long-Term Liabilities is €403 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Other Long-Term Liabilities is €403 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.45 is trading 29.1% below its estimated GF Value™ of €0.64. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for STU:640:

  • Other Long-Term Liabilities: €403 Mil
  • GF Value™: €0.64 vs. price of €0.45 (29.1% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Pharmaceutical Group Business Description

Other Exchanges 03320:Hong Kong
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
62GF Score

Get the complete analysis for STU:640

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.45
Price
€0.64
GF Value